NantHealth Inc (NASDAQ:NH) insider Ronald Allen Louks sold 6,305 shares of the business’s stock in a transaction that occurred on Thursday, September 6th. The stock was sold at an average price of $1.89, for a total value of $11,916.45. Following the transaction, the insider now directly owns 177,391 shares in the company, valued at $335,268.99. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Ronald Allen Louks also recently made the following trade(s):

  • On Monday, August 6th, Ronald Allen Louks sold 6,304 shares of NantHealth stock. The stock was sold at an average price of $3.15, for a total value of $19,857.60.
  • On Friday, July 6th, Ronald Allen Louks sold 5,749 shares of NantHealth stock. The stock was sold at an average price of $3.54, for a total value of $20,351.46.

NASDAQ NH traded down $0.09 on Friday, reaching $1.80. The stock had a trading volume of 106,872 shares, compared to its average volume of 109,475. The company has a debt-to-equity ratio of 1.34, a current ratio of 1.50 and a quick ratio of 1.48. NantHealth Inc has a 1-year low of $1.78 and a 1-year high of $5.26. The firm has a market cap of $206.90 million, a price-to-earnings ratio of -1.61 and a beta of -0.23.

NantHealth (NASDAQ:NH) last issued its quarterly earnings data on Thursday, August 9th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. NantHealth had a negative return on equity of 49.56% and a negative net margin of 124.02%. The firm had revenue of $22.05 million for the quarter, compared to analyst estimates of $24.50 million. equities analysts anticipate that NantHealth Inc will post -0.63 earnings per share for the current fiscal year.

A number of research analysts have commented on the company. Zacks Investment Research raised NantHealth from a “hold” rating to a “buy” rating and set a $2.75 price objective on the stock in a report on Friday, August 17th. BidaskClub lowered NantHealth from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 21st. ValuEngine raised NantHealth from a “hold” rating to a “buy” rating in a report on Monday, July 2nd. Finally, Canaccord Genuity reaffirmed a “hold” rating on shares of NantHealth in a report on Tuesday, July 3rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. NantHealth presently has a consensus rating of “Hold” and an average target price of $4.31.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Deutsche Bank AG grew its holdings in shares of NantHealth by 117.4% during the 4th quarter. Deutsche Bank AG now owns 45,610 shares of the company’s stock worth $137,000 after purchasing an additional 24,635 shares in the last quarter. Millennium Management LLC acquired a new stake in shares of NantHealth during the 4th quarter worth $344,000. Dimensional Fund Advisors LP grew its holdings in shares of NantHealth by 41.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 120,348 shares of the company’s stock worth $398,000 after purchasing an additional 35,445 shares in the last quarter. Finally, BlackRock Inc. grew its holdings in shares of NantHealth by 9.0% during the 2nd quarter. BlackRock Inc. now owns 2,337,249 shares of the company’s stock worth $7,735,000 after purchasing an additional 193,491 shares in the last quarter. 5.63% of the stock is currently owned by institutional investors.

NantHealth Company Profile

NantHealth, Inc, together with its subsidiaries, operates as an evidence-based personalized healthcare company in the United States and internationally. The company engages in converging science and technology through an integrated clinical platform to provide health information at the point of care.

Further Reading: Fundamental Analysis – How It Helps Investors

Insider Buying and Selling by Quarter for NantHealth (NASDAQ:NH)

Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.